ArticleAmerican journal of preventive cardiology2025
Importance of Life's Essential 8 in predicting short- and long-term incidence of cardiovascular disease: The atherosclerosis risk in communities study.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardiovascular Health of U.S. Early Adolescents Assessed by the Life's Essential 8 Metric.AJPM focus · 2026Article
- Higher Neighborhood Social Vulnerability is Associated with Lower Life's Essential 8 Cardiovascular Health Scores: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.medRxiv : the preprint server for health sciences · 2026Article
- AJPC 2025 in review: A year of growth & clearer mandate for actionable prevention.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As is acknowledged that there is a strong negative association between Life's Essential 8 (LE8) and the major adverse cardiovascular events (MACE). However, from the perspective of primary prevention of cardiovascular diseases (CVD), it is more valuable to discover the factors to predict the incidence of CVD. We intend to explore the predictive value of LE8 for the short-term and long-term incidence of CVD in the population without CVD at baseline. Methods: Participants in the ARIC (Atherosclerosis Risk in Communities) study were studied. Logistic regression models estimated the relationship between LE8 and CVD, including coronary heart disease (CHD), atrial fibrillation (AF) and stroke. Cox proportional hazards regression models were employed to assess whether an increase in the LE8 score could reduce the short-term and long-term incidence of CVD. Results: Among the 8083 participants studied at V2, 332 (4.1%) were diagnosed with CHD, 98 (1.8%) with stroke, and 24 (0.3%) with AF. LE8 was negatively associated with the prevalence of CHD, stroke, but without statistically significant association with AF. After adjusting for other cardiovascular-related risk factors, LE8 was still negatively associated with stroke (OR:0.959; 95%CI, 0.943-0.976; P<0.001). During the short-term follow-up, for each 1-point increase in the LE8 score, the risks of CHD, stroke, and AF decreased by 6.5%, 5.4%, and 5.1% respectively (the hazard ratio values were 0.935, 0.946, and 0.949). Whether LE8 was used as a continuous variable or a categorical variable, the higher the score, the lower the likelihood of developing CHD at the long-term follow-up. Using the ROC curve, the area under the curve (AUC) of LE8 for predicting the 5-year, 15-year, and 25-year incidence of CHD was 0.77, 0.696, and 0.644, respectively. Conclusions: A higher LE8 score is consistently associated with a lower probability of the incidence of CHD during both short-term and long-term follow-up periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.